Remedia 500mg №10 pills


More info

Remedia 500mg №10 pills

Composition and release form

Remedia film-coated pills
1 tab. contains levofloxacin (in the form of hemihydrate) 250 and 500 mg; in packing of 5 and 10 pieces.

pharmachologic effect

Remedia - fluoroquinolone, a broad spectrum antimicrobial bactericidal agent. It blocks DNA gyrase (topoisomerase II) and topoisomerase IV, violates supercoiling and stitching of DNA breaks, suppresses DNA synthesis, causes profound morphological changes in the cytoplasm, cell wall and membranes of bacteria. In vitro activity: Sensitive microorganisms (minimum inhibitory concentration less than 2 mg / l). Aerobic gram-positive microorganisms: Corynebacterium diphtheriae, Enterococcus spp. (including Enterococcus faecalis), Listeria monocytogenes, Staphylococcus spp. (coagulase-negative methicillin-sensitive / moderately sensitive strains), including Staphylococcus aureus (methicillin-sensitive strains), Staphylococcus epidermidis (methicillin-sensitive strains), Staphylococcus spp. (leukotoksinsoderzhaschie); Streptococcus spp. groups C and G, Streptococcus agalactiae, Streptococcus pneumoniae (penicillin-sensitive / moderately sensitive / resistant strains), Streptococcus pyogenes, Streptococcus of the viridans group (penicillin-sensitive / resistant strains). Aerobic gram-negative microorganisms: Acinetobacter spp. (including Acinetobacter baumannii), Actinobacillus actinomycetemcomitans, Citrobacter freundii, Eikenella corrodens, Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter spp. (including Enterobacter cloacae), Escherichia coli, Gardnerella vaginalis, Haemophilus ducreyi, Haemophilus influenzae (ampicillin-sensitive / resistant strains), Haemophilus parainfluenzae, Helicobacter pylori, Klebsiella spp. (including Klebsiella oxytoca, Klebsiella pneumoniae), Moraxella catarrhalis (producing and non-producing beta-lactamase strains), Morganella morganii, Neisseria gonorrhoeae (producing and non-producing penicillinase strains), Neisherosis, iisherose, iissera, iissera, iissera, iissera, neisseria, neissera, neisserie, neistose, etc. (including Pasteurella canis, Pasteurella dagmatis, Pasteurella multocida), Proteus mirabilis, Proteus vulgaris, Providencia spp. (including Providencia rettgeri, Providencia stuartii), Pseudomonas spp. (including Pseudomonas aeruginosa), Serratia spp. (including Serratia marcescens), Salmonella spp. Anaerobic microorganisms: Bacteroides fragilis, Bifidobacterium spp., Clostridium perfringens, Fusobacterium spp., Peptostreptococcus spp., Propionibacterium spp., Veilonella spp. Dr. Microorganisms: Bartonella spp., Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Legionella spp. (including Legionella pneumophila), Mycobacterium spp. (including Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma hominis), Mycoplasma pneumoniae, Rickettsia spp., Ureaplasma urealyticum. Moderately sensitive microorganisms (minimum inhibitory concentration of more than 4-8 mg / l): Aerobic gram-positive microorganisms: Corynebacterium urealyticum, Corynebacterium xerosis, Enterococcus faecium, Staphylococcus epidermidis (methicillin-resistant strains), Staphylococcus hyphromayoemology, anohytophicopycology, anesthetic, hygiene, anemogymicology, anesthetic; Aerobic gram-negative microorganisms: Burkholderia cepacia, Campylobacter jejuni, Campylobacter coli. Anaerobic microorganisms: Bacteroides thetaiotaomicron, Bacteroides vulgatus, Bacteroides ovatus, Prevotella spp., Porphyromonas spp. Resistant microorganisms (minimum inhibitory concentration of more than 8 mg / l): Aerobic gram-positive microorganisms: Corynebacterium jeikeium, Staphylococcus aureus (methicillin-resistant strains), other Staphylococcus spp. (coagulase-negative methicillin-resistant strains). Aerobic gram-negative microorganisms: Alcaligenes xylosoxidans. Dr. Microorganisms: Mycobacterium avium.


Infections caused by levofloxacin-sensitive pathogens: lower respiratory tract (exacerbation of chronic bronchitis, community-acquired pneumonia), acute sinusitis, urinary tract and kidney (including pyelonephritis), skin and soft tissue, chronic bacterial prostatitis, septicemia / bacteremia (associated with previously indicated indications), intra-abdominal infection, tuberculosis (complex therapy of drug-resistant forms).


Hypersensitivity, epilepsy, affection of tendons during previous treatment with quinolones, pregnancy, lactation, childhood and adolescence (up to 18 years).

Use during pregnancy and lactation
Levofloxacin is contraindicated for use during pregnancy and lactation (breastfeeding).

Dosage and administration

Remedia is taken orally, before meals or in between meals, without chewing, drinking plenty of fluids. With exacerbation of chronic bronchitis - 250-500 mg 1 time per day for 7-10 days. In community-acquired pneumonia, 500 mg 1-2 times a day for 7-14 days. With uncomplicated urinary tract infections - 250 mg 1 time per day for 3 days. With complicated urinary tract infections - 250 mg 1 time per day for 7-10 days. With infections of the skin and soft tissues - by mouth 250-500 mg 1-2 times a day for 7-14 days. When septicemia / bacteremia - 500 mg 1-2 times a day for 10-14 days. With intra-abdominal infection - 500 mg 1 time per day for 7-14 days (in combination with antibacterial drugs acting on anaerobic microflora). With chronic bacterial prostatitis - 500 mg 1 time per day for 28 days. With tuberculosis (as part of complex therapy) - 500 mg 1-2 times a day, the course of treatment is up to 3 months.

Side effects

On the part of the digestive system: nausea, vomiting, diarrhea (including blood), indigestion, loss of appetite, abdominal pain, pseudomembranous colitis; increased activity of liver transaminases, hyperbilirubinemia, hepatitis, dysbacteriosis. On the part of the cardiovascular system: lowering blood pressure, vascular collapse, tachycardia, prolongation of the Q-T interval. Metabolism: hypoglycemia (increased appetite, increased sweating, tremors). Nervous system disorders: headache, dizziness, weakness, drowsiness, insomnia, tremor, anxiety, paresthesias, fear, hallucinations, confusion, depression, movement disorders, convulsions. From the senses: visual impairment, hearing, smell, taste and tactile sensitivity.On the part of the musculoskeletal system: arthralgia, muscular weakness, myalgia, tendon rupture, tendonitis. From the urinary system: hypercreatininemia, interstitial nephritis, acute renal failure. From the side of blood-forming organs: eosinophilia, hemolytic anemia, leukopenia, neutropenia, agranulocytosis, thrombocytopenia, pancytopenia, hemorrhages. Allergic reactions: photosensitization, itching and flushing of the skin, swelling of the skin and mucous membranes, urticaria, malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), bronchospasm, asphyxiation, anaphylactic shock, allergic necrolysis, anesthetic, nephrolysis syndrome, bronchospasm, asphyxiation, anaphylactic necrolysis, leukemia, bronchospasm, asphyxia, anaphylactic necrolysis Other: asthenia, exacerbation of porphyria, rhabdomyolysis, persistent fever, development of superinfection.

special instructions

After normalization of body temperature, it is recommended to continue treatment for at least 48-78 h. The duration of intravenous infusion of 500 mg (100 ml of infusion solution) should be at least 60 minutes. During treatment, it is necessary to avoid solar and artificial UV irradiation in order to avoid damage to the skin (photosensitization). When signs of tendinitis, pseudomembranous colitis appear, levofloxacin is immediately canceled. It should be borne in mind that in patients with a history of brain damage (stroke, severe injury), seizures may develop, and glucose-6-phosphate dehydrogenase deficiency may lead to hemolysis. In severe community-acquired pneumonia caused by Streptococcus pneumoniae, levofloxacin may not provide the optimal therapeutic effect. During the period of treatment, care must be taken when driving and engaging in other potentially hazardous activities that require increased concentration and psychomotor reactions.


Increases T1 / 2 cyclosporine. The effect is reduced by drugs that inhibit intestinal motility, sucralfate, Al3 + and Mg2 + -containing antacid drugs and salts of Fe (a break between taking at least 2 hours is necessary). NSAIDs, theophylline increases the risk of seizures, GCS increases the risk of tendon rupture. When used simultaneously with indirect anticoagulants derived from coumarin, monitoring of INR is necessary. Cimetidine and drugs blocking tubular secretion, slow down the excretion.

Storage conditions

The drug should be stored out of the reach of children, protected from light at a temperature of from 10 ° to 25 ° C.

Expiration date - 2 years

It is a drug. Consultation with a doctor is required.